RxDoctor Payments Data

Melissa Irvin Sahm

Adult Health · Owings Mills, MDNPI 1356978530

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Among adult health clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,170in general payments, 2019–2025

Across 306 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$558
  • Pfizer$549
  • Lilly USA, LLC$528
  • AstraZeneca$274
  • Bayer$223
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,170 in reported general payments places this provider in the 90th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$34,688
Medicare patients
131
Services billed
452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$14,278
Atorvastatin Calcium134$1,673
Losartan Potassium51$1,049
Rosuvastatin Calcium40$940
Famotidine32$722
Metoprolol Succinate41$679
Montelukast Sodium20$499
Amlodipine Besylate55$457
Omeprazole29$427
Escitalopram Oxalate22$381
Levothyroxine Sodium40$370
Gabapentin22$331
Albuterol Sulfate HfaAlbuterol Sulfate12$272
Atenolol13$249
Pantoprazole Sodium16$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,261$14,27814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 542 adult health providers in Maryland.

Other adult health in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →